SFC031-03-03

General

Cell Line

hPSCreg name STBCi320-A
Cite as:
STBCi320-A (RRID:CVCL_WU51)
Alternative name(s)
SFC031-03-03
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi295-B
(SFC847-03-08)
Donor diseases:
Parkinson disease
UOXFi002-B
(MK082-30)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi003-A
(MK088-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi267-A
(SFC027-03-02)
Donor diseases:
Parkinson disease
STBCi023-B
(SFC829-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi025-C
(SFC834-03-10)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi005-A
(SFC833-03-01)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-A
(SFC855-03-06)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi085-A
(SFC866-03-06)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi083-B
(SFC830-04-08)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi088-A
(SFC872-03-05)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi090-B
(SFC867-04-12)
Donor diseases:
Parkinson disease
STBCi005-B
(SFC833-03-05)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi005-C
(SFC833-03-14)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-B
(SFC855-03-08)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi007-C
(SFC855-03-01)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi002-A
(MK082-26)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi003-C
(MK088-7)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi258-A
(SFC090-03-07)
Donor diseases:
Parkinson disease
STBCi259-A
(SFC032-03-07)
Donor diseases:
Parkinson disease
STBCi265-A
(SFC121-03-02)
Donor diseases:
Parkinson disease
STBCi268-A
(SFC077-03-04)
Donor diseases:
Parkinson disease
STBCi279-A
(SFC063-03-01)
Donor diseases:
Parkinson disease
STBCi281-A
(SFC167-03-04)
Donor diseases:
Parkinson disease
STBCi282-A
(SFC138-03-05)
Donor diseases:
Parkinson disease
STBCi023-A
(SFC829-03-02)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-C
(SFC829-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi288-A
(SFC028-03-08)
Donor diseases:
Parkinson disease
STBCi289-A
(SFC030-03-02)
Donor diseases:
Parkinson disease
STBCi025-B
(SFC834-03-03)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi290-A
(SFC069-03-01)
Donor diseases:
Parkinson disease
STBCi291-A
(SFC080-03-04)
Donor diseases:
Parkinson disease
STBCi294-A
(SFC844-03-12)
Donor diseases:
Parkinson disease
EDi001-A
(AST22, AST23, SAMEA3319992)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
UOXFi001-A
(MK071-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-B
(MK071-3)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi024-A
(SFC831-03-01)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-C
(SFC831-03-05)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
UOXFi007-A
(MK002-4)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi008-B
(MK144-7)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi019-C
(SFC828-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi004-A
(SFC832-03-19)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi084-A
(SFC871-03-12)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
STBCi084-C
(SFC871-03-09)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
ESi001-A
(SPO2#1)
Donor diseases:
Parkinson disease
EDi008-B
(G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
Last update 1st September 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator StemBANCC (STBC)
Distributors

External Databases

BioSamples SAMEA5859484
EBiSC STBCi320-A
Cellosaurus CVCL_WU51
Wikidata Q98132854

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 55-59

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Sporadic Parkinson's disease / dyskinesia
The donor is affected.
Synonyms
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans

External Databases (Donor)

BioSamples SAMEA5859483

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? NRES Committee South Central - Hampshire A
Approval number 13/SC/0179
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? NRES Committee South Central - Hampshire A
Approval number 13/SC/0179
Do you have obligations to third parties in regard to the use of the cell line? Yes
Please describe: DNA sequencing can only be performed for research into donors specified condition. Material shall not be sold, transplanted into any human being or used to create egg or sperm cells (gametes) or embryos. The material shall not be used for direct exploitation. For the purposes of this, Direct exploitation means to develop for commericalization or to commercialize the Material.
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Age of donor (at collection) 55-59
Passage number reprogrammed 3

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Notes on reprogramming vector detection Cytotune 2.0
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-60
Yes
NANOG
Yes
Morphology pictures

Microbiology / Virus Screening

Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage:

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Identity to parent fibroblasts confirmed. Normal karyotype..
Passage number: 10
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)